J&J to buy Austin's Ollin Biosciences for up to $3.3B
What's the deal? Johnson & Johnson is set to acquire Austin-based Ollin Biosciences for up to $3.3 billion, giving the healthcare giant a foothold in retinal medicines. The reported structure is $2.2 billion upfront plus up to $1.2 billion tied to milestones.
Who is Ollin? The biotech startup was founded in 2023 and came out of stealth mode just last year with $100 million in funding. Its lead candidate is planned for late-stage trials in diabetic macular edema and wet age-related macular degeneration.
What's the endgame? Retinal medicines are a gap in J&J's portfolio, and Ollin would help fill it. The milestone payments mean the price reflects both the opportunity and the clinical risk.
Why now? The deal lands amid a sharp pickup in biotech dealmaking, with biopharma M&A reaching an eight-year high in October 2026, according to BioWorld. J&J has been active, recently buying oncology developer Firefly Bio for $1 billion and Intra-Cellular Therapies for $14.6 billion.
What could go wrong? The talks were first reported by the Financial Times and had not been confirmed by either company in Reuters' coverage. More than a third of the headline value hinges on clinical milestones that may not be met.
The signal: For a two-year-old startup, a multibillion-dollar exit underscores how far big pharma will reach — and pay — to plug portfolio gaps while the M&A window stays open.
Read more: bizjournals.com · jnj.com
Image credit: Generated with Gemini